Therefore, a phase II study using 600 mg of DKN-01 in combination with the immune checkpoint inhibitor nivolumab [an anti-Programmed cell Death 1 (PD-1) antibody] was started for patients with advanced biliary tract cancer (NCT04057365). This evidence concerns the gene PDCD1 and biliary tract neoplasm.